Cowen Downgrades Life Technologies Amid Acquisition Chatter | GenomeWeb

NEW YORK (GenomeWeb News) – Citing a recent run up in Life Technologies' stock fueled by speculation that it may be positioning itself to be bought, investment bank Cowen & Co. today downgraded the Carlsbad, Calif.-based firm to Neutral from Outperform.

Analyst Doug Schenkel added in a research note that amid reports that several potential buyers may be preparing to bid on Life Tech, "[w]e do believe there is a transaction to be done (at the right price)."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.